Ginkgo Bioworks DNA
Ginkgo Bioworks Holdings, Inc. · NYSE · Biological Products, (No Diagnostic Substances)
$12.74-4.35%close on Oct. 29, 2026 · volume 2.9M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 19, 2026 | Steven P. Coen See remarks | Sold | 766 | $10.14 | $7,770 |
| Oct. 19, 2026 | Barry Canton 10% owner | Sold | 18,803 | $10.14 | $190,719 |
| Oct. 19, 2026 | Barry Canton 10% owner · indirect | Sold | 22,369 | $10.14 | $226,889 |
| Oct. 19, 2026 | Reshma P. Shetty See remarks, director, 10% owner | Sold | 22,369 | $10.14 | $226,889 |
| Oct. 19, 2026 | Reshma P. Shetty See remarks, director, 10% owner · indirect | Sold | 18,803 | $10.14 | $190,719 |
| Oct. 19, 2026 | Jason R. Kelly See remarks, director | Sold | 45,682 | $10.14 | $463,353 |
| Oct. 5, 2026 | Steven P. Coen See remarks | Sold | 2,403 | $15.00 | $36,045 |
| Sept. 15, 2026 | Christian O. Henry director | Sold | 5,000 | $7.08 | $35,405 |
| Aug. 24, 2026 | Steven P. Coen See remarks | Sold | 330 | $6.98 | $2,302 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 15 →Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedGinkgo Bioworks Schedules Third Quarter 2026 Results Presentation for November 5, 2026